RIGL
RIGL clinical trials: RIGEL PHARMACEUTICALS INC
Every trial on ClinicalTrials.gov where RIGEL PHARMACEUTICALS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 44
- Trials linked
- 28
- As lead sponsor
- 16
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RIGL on the catalyst calendar · RIGL registry changes
- Primary completion Dec 2027Sponsor estimatePhase 1/Phase 2NCT05308264Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)Rigel Pharmaceuticals · Low Risk Myelodysplastic SyndromesRecruitingRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 2NCT06161974Study of Olutasidenib and Temozolomide in HGGRigel Pharmaceuticals · High Grade GliomaRecruitingRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 30, 2027Sponsor estimatePhase 4NCT07704658Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsRigel Pharmaceuticals · NSCLC (Non-small Cell Lung Cancer)RecruitingRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2027Sponsor estimatePhase 4NCT07486713Olutasidenib DDI Study in Patients With IDH1 Mutation Positive MalignanciesRigel Pharmaceuticals · AML (Acute Myeloid Leukemia)RecruitingRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 17, 2022ActualNo phase registeredNCT04904276Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient...Rigel Pharmaceuticals · ITPTerminatedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2, 2020ActualPhase 3NCT02077192Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)Rigel Pharmaceuticals · Immune Thrombocytopenic PurpuraCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 5, 2022ActualPhase 3NCT04629703Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19...Rigel Pharmaceuticals · Covid19CompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 11, 2022ActualPhase 3NCT03764618A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHARigel Pharmaceuticals · Warm Antibody Autoimmune Hemolytic AnemiaCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2024Sponsor estimatePhase 3NCT04138927A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaRigel Pharmaceuticals · Warm Antibody Autoimmune Hemolytic AnemiaEnrolling by invitationRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2019ActualPhase 2NCT02612558A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)Rigel Pharmaceuticals · Warm Antibody Autoimmune Hemolytic AnemiaCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 23, 2018ActualPhase 2NCT02112838Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) NephropathyRigel Pharmaceuticals · IGA NephropathyCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2016ActualPhase 3NCT02076412A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)Rigel Pharmaceuticals · Immune Thrombocytopenic PurpuraCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 21, 2016ActualPhase 3NCT02076399A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)Rigel Pharmaceuticals · Immune Thrombocytopenic PurpuraCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03363334Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITPRigel Pharmaceuticals · Immune Thrombocytopenic PurpuraNo longer availableRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2009ActualPhase 2NCT00665626Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)Rigel Pharmaceuticals · Rheumatoid ArthritisCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualPhase 2NCT02040623Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)Rigel Pharmaceuticals · Chronic Graft-versus-host DiseaseCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2014ActualPhase 2NCT01900249To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis SiccaRigel Pharmaceuticals · Keratoconjunctivitis SiccaCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2010ActualPhase 2NCT00798096Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell LymphomaRigel Pharmaceuticals · T Cell LymphomaCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2010ActualPhase 1/Phase 2NCT00446095Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell LymphomaRigel Pharmaceuticals · LymphomaCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2013ActualPhase 2NCT01591044A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate AsthmaRigel Pharmaceuticals · AsthmaCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2009ActualPhase 2NCT00665925Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid ArthritisRigel Pharmaceuticals · Rheumatoid ArthritisCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2013ActualPhase 2NCT01597050Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) LesionsRigel Pharmaceuticals · Lupus Erythematosus, DiscoidCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2010ActualPhase 2NCT00706342Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)Rigel Pharmaceuticals · Purpura, Thrombocytopenic, IdiopathicCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2015ActualPhase 2NCT02433236Open Label Study of Fostamatinib in the Treatment of IgA NephropathyRigel Pharmaceuticals · IGA NephropathyWithdrawnRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2013ActualPhase 1NCT01733992A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye DiseaseRigel Pharmaceuticals · Keratoconjunctivitis SiccaCompletedRIGLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 19 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner